Skip to main content

Advertisement

Table 2 Summary of efficacy for triple antiplatelet therapy in randomised controlled trials (significant effects are in bold).

From: Triple antiplatelet therapy for preventing vascular events: a systematic review and meta-analysis

Patients Intervention Myocardial infarction Composite vascular event Death
   Triple events/total Control events/total OR* (95% CI) Triple events/total Control events/total OR* (95% CI) Triple events/total Control events/total OR* (95% CI)
NSTE-ACS GP IIb/IIIa 195/1848 232/1558 0.70 (0.56-0.88) 202/1848 244/1558 0.69 (0.55-0.86) 14/1848 19/1558 0.72 (0.36-1.43)
STEMI GP IIb/IIIa 32/1771 117/1683 0.26 (0.17-0.38) 88/1771 203/1683 0.39 (0.30-0.51) 56/1771 78/1683 0.69 (0.49-0.99)
  Cilostazol 2/30 1/30 2.07 (0.18-24.15)       
Elective PCI GP IIb/IIIa 170/3615 244/3614 0.77 (0.54-1.11) 195/3515 268/3514 0.78 (0.54-1.12) 33/3515 37/3514 0.90 (0.55-1.46)
  Cilostazol 17/1439 16/1437 1.07(0.53-2.16) 46/1408 57/1409 0.86(0.40-1.85) 20/1439 29/1437 0.70(0.39-1.25)
  Clopidogrel 2/60 2/60 0.95 (0.13-6.74)       
  1. *Odds ratios (OR) were calculated from random effect models.
  2. CI, confidence interval; NSTE-ACS, non-ST elevation acute coronary syndromes; STEMI, ST elevation myocardial infarction; PCI, percutaneous coronary intervention.